Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States
Mycoses · 2025-09 · 68 (9)
DOI: 10.1111/myc.70114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, online erschienen am 17.09.2025. Verfasst von Ilana Reinhold und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicin…. Hauptthemen laut MEDLINE: Antifungal Agents, Echinocandins, Candidiasis, Invasive. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basilea Pharmaceutica, Amplyx Pharmaceuticals Inc., F2G Biotech GmbH.
Abstract (Originalsprache)
Background
Rezafungin, a novel echinocandin with once‐weekly intravenous dosing, offers potential advantages for outpatient parenteral antifungal therapy (OPAT) in invasive candidiasis (IC). While clinical trial data support its efficacy and safety, real‐world experience remains limited.
Methods
A retrospective analysis of patients treated with rezafungin across Germany, Italy, Spain, and the United States between January 2024 and June 2025 was conducted. Data was collected via the FungiScope registry. Clinical characteristics, indications for rezafungin, outcomes, safety, and logistical aspects of administration were evaluated.
Results
Fifteen patients were included, fourteen with IC; one with chronic pulmonary aspergillosis. Regarding patients with IC, the median age was 65.5 years; 43% were female. The most frequently identified pathogens were Candida glabrata (57%) and Candida parapsilosis (21%). Primary indications for rezafungin were intravascular (36%) and osteoarticular infections (36%). Rezafungin was mainly selected to enable OPAT (86%) or due to fluconazole resistance (36%) or drug–drug interactions (14%). The median treatment duration was 9 weeks (range: 1–38 weeks). One mild adverse event occurred (cutaneous photosensitivity), but rezafungin was otherwise well tolerated. Complete clinical or mycological response was observed in 36% at day 30, and partial response in 50% of patients. Access differed substantially across centres due to administrative and reimbursement hurdles, affecting treatment transition to rezafungin in 71% of patients with IC.
Conclusions
Rezafungin was effective and well tolerated in this cohort, particularly in patients requiring long‐term treatment. Administrative and logistical hurdles remain significant barriers to its widespread use. Facilitated access and enhanced awareness may improve patient outcomes by supporting early initiation and continuity of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne, Cologne, Germany.
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Faculty of Medicine, University of Cologne, University Hosp…
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
- Unit of Infectious Diseases, Santa Chiara Hospital, Azienda Provinciale per i Servizi Sanitari, Trento, Italy.
- Centre for Medical Sciences (CISMed), University of Trento, Trento, Italy.
- Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
ORCID-Profile: Ilana Reinhold, Giovanni Mori, Massimiliano Lanzafame, Alessandro Limongelli, Antonio Vena, Julia Götz, Frank Hanses, Lukas Tometten, Ana Soriano-Martin, Maricela Valerio, Jose A Vazquez, Laman Rahimli, Nijat Azimli, Ertan Sal, Jon Salmanton-García, Natalia Vasenda, Jannik Stemler, Oliver A Cornely, Danila Seidel
Förderung
- Basilea Pharmaceutica
- Amplyx Pharmaceuticals Inc.
- F2G Biotech GmbH
- Cidara Therapeutics
- Melinta Therapeutics LLC
- Matinas BioPharma Holdings Inc.
- Pfizer Inc.
- Mundipharma Research Limited
Zitieren
APA
Reinhold, I., Mori, G., Lanzafame, M., Limongelli, A., Vena, A., Götz, J., Bauernfeind, S., Hanses, F., Tometten, L., Mayer, M., Rieke, A., Soriano-Martin, A., Valerio, M., Vazquez, J. A., Yue, P., Rahimli, L., Azimli, N., Sal, E., Salmanton-García, J., …, & Seidel, D. (2025). Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States. Mycoses, 68(9). https://doi.org/10.1111/myc.70114
Vancouver
Reinhold I, Mori G, Lanzafame M, Limongelli A, Vena A, Götz J, et al. Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States. Mycoses. 2025;68(9). doi:10.1111/myc.70114
BibTeX
@article{Reinhold2025,
author = {Reinhold, Ilana and Mori, Giovanni and Lanzafame, Massimiliano and Limongelli, Alessandro and Vena, Antonio and Götz, Julia and Bauernfeind, Stilla and Hanses, Frank and Tometten, Lukas and Mayer, Michael and Rieke, Ansgar and Soriano-Martin, Ana and Valerio, Maricela and Vazquez, Jose A and Yue, Patrick and Rahimli, Laman and Azimli, Nijat and Sal, Ertan and Salmanton-García, Jon and Vasenda, Natalia and Sprute, Rosanne and Stemler, Jannik and Wingen-Heimann, Sebastian and Cornely, Oliver A and Seidel, Danila},
title = {Rezafungin Utilisation in Real Life— FungiScope Results From Europe and the United States},
journal = {Mycoses},
year = {2025},
volume = {68},
number = {9},
doi = {10.1111/myc.70114}
}
EUVIMED